Cerebral Vasoreactivity, Apolipoprotein E, and the Risk of Dementia A Population-Based Study

被引:46
作者
Wolters, Frank J. [1 ,2 ]
de Bruijn, Renee F. A. G. [1 ,2 ]
Hofman, Albert [2 ]
Koudstaal, Peter J. [1 ]
Ikram, M. Arfan [1 ,2 ,3 ]
机构
[1] Erasmus MC, Dept Neurol, Rotterdam, Netherlands
[2] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands
[3] Erasmus MC, Dept Radiol, Rotterdam, Netherlands
关键词
Alzheimer disease; apolipoprotein E; dementia; epidemiology; hypercapnia; vasoreactivity; SMALL-VESSEL DISEASE; BLOOD-BRAIN-BARRIER; WHITE-MATTER HYPERINTENSITIES; PLACEBO-CONTROLLED TRIAL; ALZHEIMER-DISEASE; NEUROVASCULAR DYSFUNCTION; CEREBROVASCULAR-DISEASE; MOLECULAR-MECHANISMS; VASOMOTOR REACTIVITY; CEREBROSPINAL-FLUID;
D O I
10.1161/ATVBAHA.115.306768
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Cerebral vasoreactivity (CVR) is a key factor in maintenance of continuous cerebral perfusion and a marker of (micro)vascular damage. We aimed to determine the longitudinal relation between CVR and the risk of dementia in the general population. Approach and Results We determined CVR in nondemented participants who underwent transcranial Doppler with induced hypercapnia from 1997 to 1999, as part of the ongoing population-based Rotterdam Study. We used a Cox model to determine the risk of dementia in relation to CVR, adjusted for age, sex, cardiovascular risk factors, and carotid intima-media thickness. We furthermore determined decline on a cognitive test battery in relation to CVR, using linear mixed models. Among 1629 participants (meanSD age 70.6 +/- 6.2 years, 46.2% female) with a mean follow-up of 11.5 years, 209 were diagnosed with dementia, of whom 171 had Alzheimer disease. Higher CVR at baseline was associated with lower risk of dementia (adjusted hazard ratio, 95% confidence interval, per SD increase: 0.87, 0.75-1.00) and Alzheimer disease (adjusted hazard ratio, 0.84; 0.71-0.99). This association was more profound in APOE epsilon 4 carriers than in noncarriers (adjusted hazard ratio for all dementia: 0.77, 0.60-0.98 versus 0.89, 0.73-1.07). Performance on cognitive tests at baseline was better with higher CVR (g-factor: P=0.02), but during 3 cognitive assessments over 11 years of follow-up, higher CVR at baseline was associated with less decline in test scores on the Stroop reading and interference tasks in APOE epsilon 4 carriers only (P=0.01 and 0.02, respectively). Conclusions Impaired CVR is associated with an increased risk of dementia in the general population.
引用
收藏
页码:204 / 210
页数:7
相关论文
共 50 条
  • [21] Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease
    Jaturapatporn, Darin
    Isaac, Mokhtar Gad El Kareem Nasr
    McCleery, Jenny
    Tabet, Naji
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (02):
  • [22] The roles of cerebral blood flow, capillary transit time heterogeneity, and oxygen tension in brain oxygenation and metabolism
    Jespersen, Sune N.
    Ostergaard, Leif
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2012, 32 (02) : 264 - 277
  • [23] Significant negative correlations between capillary expressed eNOS and Alzheimer lesion burden
    Jeynes, Brian
    Provias, John
    [J]. NEUROSCIENCE LETTERS, 2009, 463 (03) : 244 - 248
  • [24] Endothelial nitric oxide: protector of a healthy mind
    Katusic, Zvonimir S.
    Austin, Susan A.
    [J]. EUROPEAN HEART JOURNAL, 2014, 35 (14) : 888 - 894
  • [25] Cerebrovascular Function in Aging and Dementia: A Systematic Review of Transcranial Doppler Studies
    Keage, Hannah A. D.
    Churches, Owen F.
    Kohler, Mark
    Pomeroy, Danielle
    Luppino, Rocco
    Bartolo, Michelle L.
    Elliott, Scott
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA, 2012, 2 (01): : 258 - 270
  • [26] Associations Between Cerebral Small-Vessel Disease and Alzheimer Disease Pathology as Measured by Cerebrospinal Fluid Biomarkers
    Kester, Maartje I.
    Goos, Jeroen D. C.
    Teunissen, Charlotte E.
    Benedictus, Marije R.
    Bouwman, Femke H.
    Wattjes, Mike P.
    Barkhof, Frederik
    Scheltens, Philip
    van der Flier, Wiesje M.
    [J]. JAMA NEUROLOGY, 2014, 71 (07) : 855 - 862
  • [27] Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study
    Kivipelto, Miia
    Ngandu, Tiia
    Laatikainen, Tiina
    Winblad, Bengt
    Soininen, Hilkka
    Tuomilehto, Jaakko
    [J]. LANCET NEUROLOGY, 2006, 5 (09) : 735 - 741
  • [28] la Torre de JC, 2012, CARDIOVASC PSYCHIAT, V2012
  • [29] Placebo-Controlled Trial of High-Dose Atorvastatin in Patients With Severe Cerebral Small Vessel Disease
    Lavallee, Philippa C.
    Labreuche, Julien
    Gongora-Rivera, Fernando
    Jaramillo, Arturo
    Brenner, David
    Klein, Isabelle F.
    Touboul, Pierre-Jean
    Vicaut, Eric
    Amarenco, Pierre
    [J]. STROKE, 2009, 40 (05) : 1721 - 1728
  • [30] Amyloid β Interaction with Receptor for Advanced Glycation End Products Up-Regulates Brain Endothelial CCR5 Expression and Promotes T Cells Crossing the Blood-Brain Barrier
    Li, Man
    Shang, De-Shu
    Zhao, Wei-Dong
    Tian, Li
    Li, Bo
    Fang, Wen-Gang
    Zhu, Li
    Man, Shu-Mei
    Chen, Yu-Hua
    [J]. JOURNAL OF IMMUNOLOGY, 2009, 182 (09) : 5778 - 5788